SCHEMBL17526014

SCHEMBL17526014

CCOc1ncc(-c2cc(C(=O)Nc3ccnc(CF)c3)ccc2C)cc1N1CCOCC1

nearest known ligand 0.80

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 20/20 0.80
BRAF P15056 20/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16121455 0.89 RAF1 (1.00) RAF1BRAF
SCHEMBL17526055 0.87 RAF1 (0.90) RAF1BRAF
SCHEMBL17526035 0.86 RAF1 (0.80) RAF1BRAF
SCHEMBL17526030 0.85 RAF1 (0.80) RAF1BRAF
SCHEMBL16100314 0.85 RAF1 (1.00) RAF1BRAF
SCHEMBL16035556 0.85 RAF1 (1.00) RAF1BRAF
SCHEMBL17526038 0.84 RAF1 (0.90) RAF1BRAF
SCHEMBL16121195 0.84 RAF1 (1.00) RAF1BRAF
SCHEMBL19327188 0.84 RAF1 (0.90) RAF1BRAF
SCHEMBL16121183 0.83 RAF1 (1.00) RAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS RAF1 2/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.